Status:
COMPLETED
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Pulmonary Fibrosis
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on...
Eligibility Criteria
Inclusion
- For the idiopathic pulmonary fibrosis (IPF) Cohort
- Diagnosis of IPF within 7 years of screening
- Female and males ≥ 40 years of age
- For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
- Evidence of progressive ILD within the 24 months before screening
- Female and male ≥ 21 years of age.
Exclusion
- Women of childbearing potential (WOCBP)
- Active Smokers
- Current malignancy or previous malignancy up to 5 years prior to screening
- History of allergy to BMS-986278 or related compounds
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
July 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2023
Estimated Enrollment :
403 Patients enrolled
Trial Details
Trial ID
NCT04308681
Start Date
July 29 2020
End Date
September 22 2023
Last Update
February 24 2025
Active Locations (119)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0032
Birmingham, Alabama, United States, 35294
2
Local Institution
Phoenix, Arizona, United States, 85006
3
Local Institution - 0028
Los Angeles, California, United States, 90024
4
Local Institution - 0043
Stanford, California, United States, 94305-528